A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non–Small Cell Lung Cancer Cells  by Chen, Chi-Wei et al.
www.neoplasia.com
Volume 18 Number 4 April 2016 pp. 199–212 199A Potent Derivative of
Indolizino[6,7-b]Indole for
Treatment of Human Non–Small
Cell Lung Cancer Cells1,2Chi-Wei Chen*,†, Ming-Hsi Wu†, Yi-Fan Chen*,†,
Tsai-Yi Yen‡, Yi-Wen Lin†, Shu-Hsin Chao†,
Satishkumar Tala†, 3, Tung-Hu Tsaic,
Tsann-Long Su† and Te-Chang Lee*,†, §
*Institute of Biopharmaceutical Sciences, National
Yang-Ming University, Taipei 11221, Taiwan; †Institute of
Biomedical Sciences, Academia Sinica, Taipei 11529,
Taiwan; ‡Institute of TraditionalMedicine, National Yang-Ming
University, Taipei 11221, Taiwan; §Institute of Pharmacology,
National Yang-Ming University, Taipei 11221, TaiwanAbstract
The therapeutic effect in non–small cell lung cancer (NSCLC) patients is limited because of intrinsic and acquired
resistance. Thus, an unmet need exists for the development of new drugs to improve the therapeutic efficacy in
NSCLC patients. In this study, the novel small molecule indolizino[6,7-b]indole derivative BO-1978 was selected to
evaluate its therapeutic effects on NSCLC and its preclinical toxicity in animal models. An in vitro cytotoxicity assay
revealed that BO-1978 significantly suppressed the growth of various NSCLC cell lines with or without mutations
in epidermal growth factor receptor (EGFR). Mechanistically, we demonstrated that BO-1978 exhibited multiple
modes of action, including inhibition of topoisomerase I/II and induction of DNA cross-linking. Treatment of NSCLC
cells with BO-1978 caused DNA damage, disturbed cell cycle progression, and triggered apoptotic cell death.
Furthermore, BO-1978 significantly suppressed the growth of EGFR wild-type and mutant NSCLC tumors in
xenograft tumor and orthotopic lung tumor models with negligible body weight loss. The combination of BO-1978
with gefitinib further suppressed EGFR mutant NSCLC cell growth in xenograft tumor and orthotopic lung tumor
models. Preclinical toxicity studies showed that BO-1978 administration did not cause apparent toxicity in mice.
Based on its significant therapeutic efficacy and low drug toxicity, BO-1978 is a potential therapeutic agent for
treatment of NSCLC.
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Lung cancer causes one third of cancer deaths worldwide because
of its high incidence and high mortality [1]. Non–small cell lung
cancer (NSCLC) accounts for approximately 85% of lung cancer cases
and has a 16% 5-year survival rate [2]. Curative NSCLC treatments
include surgery, radiation therapy, chemotherapy, and targeted therapy.
Cisplatin, carboplatin,mitomycinC, paclitaxel, ifosfamide, doxorubicin,
irinotecan, and vinorelbine are frequently used as therapeutic agents
for treatment of patients with NSCLC, either alone or in combination
[3, 4]. Unfortunately, the responsiveness of NSCLC to chemothera-
peutic agents is limited [5].
Because of technological advances during the past decade,
epidermal growth factor receptor (EGFR) mutations have been
identified in approximately 40% of patients with NSCLC in East Asia
and 15% of Caucasians and African Americans [6, 7]. Thus, tyrosinety
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gefitinib, and afatinib, are clinically used as targeted therapeutics to
treat NSCLC patients harboring mutations in EGFR [3, 8, 9].
Although the clinical outcome is impressive during initial treatment, the
survival rate remains to be improved because of the emergence of drug
resistance within 9 to 12 months [10], which mainly occurs because of a
T790M secondary mutation, MET (hepatocyte growth factor receptor)
amplification, or histologic transformation to small cell lung cancer [11–13].
Currently, numerous new-generation TKIs are under development [14]. In
addition, a variety of combinations of chemotherapy and targeted agents are
undergoing clinical trials to improve maintenance therapy [15].
In addition to EGFR, numerous oncogene mutations, either
targetable or nontargetable, were identified in NSCLC patients, such
as human epidermal growth factor receptor 2, MET, fibroblast
growth factor receptor 1 and 2, anaplastic lymphoma kinase, ROS1
receptor tyrosine kinase, neuregulin 1, neurotrophic tyrosine kinase
receptor type 1, RET receptor tyrosine kinase, and others [16]. For
NSCLC patients who do not harbor targetable genetic abnormalities,
platinum-based doublet chemotherapy remains the first-line treatment
[17]. Unfortunately, the outcomes are generally frustrating. Therefore,
the need exists to discover novel agents with improved efficacy and
safety profiles for the treatment of NSCLC, including patients with
wild-type EGFR, mutant EGFR, and acquired mutations that are
resistant to TKIs.
Hybrid molecules, which integrate two drug pharmacophores into
a single molecule, hold the potential to generate new compounds with
dual mechanisms of action [18]. Based on this concept, we recently
designed and synthesized a series of indolizino[6,7-b]indoles that
consist of a β-carboline group, which acts as a topoisomerase (topo) I/
II inhibitory moiety [19, 20], and a bis(hydroxymethyl)pyrrole
fragment, which acts as a DNA cross-linking moiety [18, 21, 22].
Our previous report showed that the indolizino[6,7-b]indole
derivatives were potent anticancer agents that significantly suppressed
the growth of human breast carcinoma MX-1, lung adenocarcinoma
A549, and colon cancer HT-29 xenograft tumor models [23]. Based
on the solubility and animal tolerance, we recently found that
compound [3-ethyl-6-methyl-6,11-dihydro-5H-indolizino[6,7-b]
indole-1,2-diyl]dimethanol (Figure 1A), named BO-1978, exhibited
significant cytotoxicity against the cell growth of various NSCLC cells
in vitro. This observation drew our attention to further explore the
antitumor activity of BO-1978 against NSCLC.
In this study, we evaluated the cytotoxicity of BO-1978 in a batch
of EGFR wild-type and mutant NSCLC cell lines in vitro and
performed biological assays to confirm the compound’s biochemical
activities in inducing interstrand DNA cross-links (ICLs) and
inhibiting topo I/II. The anti-NSCLC activities of BO-1978 were
investigated with xenograft and orthotopic lung models in nude mice.
In addition, we also conducted a preclinical toxicity study of
BO-1978 in animal models. Our results demonstrate that BO-1978
is a prospective compound for the treatment of patients with NSCLC.
Materials and Methods
Chemicals and Reagents
Compound BO-1978 (Figure 1A), a derivative of indolizino[6,7-
b]indoles, was synthesized as previously described [23]. Gefitinib
was purchased from Cayman Chemical Company. Other chemicals
and reagents were purchased from Sigma-Aldrich except those as
indicated elsewhere.Cell Lines and Cell Culture
The NSCLC lines used in this study were listed in Table 1. Among
them, H460, H1299, and A549 cells were obtained from the
American Type Culture Collection, and H1650 and H1975 were
provided by Dr. Tsu-An Hsu (National Health Research Institutes,
Miaoli, Taiwan). CL141, CL1-5, CL100, CL97, PC9, PC9/gef B4
[24], and CL1-5/GFP-Luciferase [25] lines were kindly provided by
Dr. Pan-Chyr Yang (National Taiwan University, Taipei, Taiwan).
CL141T was derived from CL141 xenograft from a NOD-SCID
mouse in our laboratory [26]. The luciferase overexpressed H1650
cells, designated as H1650-Luc cells, were established by transfection
of 2.5 μg of pGL4.10[Luc2] plasmid DNA (Promega) into H460
cells using 5 μl of Lipofectamine 2000 Reagent (Invitrogen) for 4
hours and cultured with 1 mg/ml of geneticin (Gibco). In general,
these cell lines were cultured in the RPMI 1640 medium (Gibco)
containing 10% fetal bovine serum (HyClone), 100 U/ml of
penicillin, 100 U/ml of streptomycin, 29.2 mg/ml of L-glutamine
(Gibco), and 10 mM HEPES (pH 7.4) at 37°C in a humidified
atmosphere with 5% CO2.
In Vitro Cytotoxicity Assays
The cytotoxicity was assayed using alamarBlue reagent (AbD
Serotec) as previously described [23]. In brief, the logarithmically
growing cells were treated with BO-1978 at serial-diluted concen-
trations or in combination with gefitinib for 72 hours at 37°C. An
aliquot of alamarBlue reagent was added. The cultures were incubated
for 4 to 6 hours, and the absorbance at 570 nm and 600 nm was read
with a plate reader. The proliferation rate was calculated according to
the manufacturer’s instruction. The values of 50% inhibition
concentration (IC50) and combination index for join treatment
were determined from dose-effect relationship using the CompuSyn
software (CompuSyn Inc., Paramus, NJ) [27].
Alkaline Gel Shift Assay
Formation of DNA cross-links was analyzed by alkaline agarose gel
electrophoresis as previously described [26]. Briefly, purified
pEGFP-N1 plasmid DNA (1500 ng) was mixed with various
concentrations (0.125 to 2 μM) of BO-1978 or cisplatin in 40 μl of
binding buffer (3 mM sodium chloride, 1 mM sodium phosphate,
pH 7.4, and 1 mM EDTA). The reaction mixture was incubated at
37°C for 2 hours. At the end of incubation, the plasmid DNA was
linearized by BamHI digestion at 37°C for 2 hours and then
precipitated with 70% ice-cold ethanol at −80°C for 16 hours. The
DNA pellets were dissolved and denatured in an alkaline buffer (0.5
N NaOH and 10 mM EDTA). An aliquot of 20 μl of DNA solution
(approximately 1500 ng) was mixed with 4 μl of six-fold DNA
loading dye and electrophoretically resolved on a 0.8% alkaline
agarose gel with a NaOH-EDTA buffer using 18 V at 4°C for 22
hours. After staining the gels with ethidium bromide solution, the
DNA was visualized under UV light.
Modified Comet Assay
As previously described [28], H460 cells were treated with various
concentrations of BO-1978 or cisplatin for 2 hours. Afterward, the
cells were irradiated with X-rays at the dose of 20 Gy. An aliquot of
80 μl of cell suspension were mixed with 400 μl of 1.2% low–melting
point agarose and plated on Fisherfinest microscope slide (Thermo
Scientific), which was previously layered with 120 μl of 1% agarose
gel. Cells were then lysed in the lysis buffer, and fragmented DNA
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Figure 1. DNA damage induced by BO-1978. (A) Chemical structure of BO-1978. (B) Formation of DNA cross-linking by BO-1978. Plasmid
DNA was treated with various concentrations (0.125 to 2 μM) of BO-1978 or cisplatin for 2 hours at 37°C. The ICL and single-strand DNA
was electrophoretically separated under alkaline conditions, as described in theMaterials andMethods section. (C) Induction of DNA ICLs
in H460 cells by BO-1978. H460 cells were treated with various concentrations (1, 5, and 10 μM) of BO-1978 or 10 μMcisplatin for 2 hours.
DNA ICLs formed in H460 cells were identified using a modified comet assay. (D) Inhibition of intracellular topo I (upper panel) and II
(lower panel) activities in H460 cells. The nuclear extracts of BO-1978–treated H460 cells (0.25 to 4 μM for 72 hours) were prepared and
incubated with pEGFP-N1 plasmid DNA and specific topo I or topo II buffer for 30 minutes at 37°C as described in the Materials and
Methods section. The relaxation of plasmid DNA was analyzed by electrophoresis. Irinotecan and etoposide served as positive controls
for topo I and topo II, respectively. (E) The DNA damage response of H460 cells to BO-1978. H460 cells were treated with BO-1978 at the
concentrations of 1 to 4 μM for 24 hours or 2 μMBO-1978 for various time periods (24 to 72 hours). γH2AX (Ser139), DNA-PK, and Rad51
protein expression levels were determined by western blotting.
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staining with 60 μl of 5 μM YOYO-1 iodide (491/509) (Invitrogen).
The tail moment of 100 cells of each treatment was analyzed with
Comet assay III software (Perceptive Instruments). The degree of
DNA ICLs present in a drug-treated sample was determined by
comparing the tail moments of the irradiated control. The formula is
percentage of DNA with ICLs = [1 – (TMdi − TMcu/TMci −
TMcu)] × 100%. TMdi means tail moment of drug-treated irradiatedsample, TMcu indicates tail moment of untreated nonirradiated
control, and TMci is tail moment of untreated irradiated control.
Topo I and II Activity Assays
The assays of topo I and II activity were performed following the
established protocols [29]. In brief, H460 cells were treated with
various concentrations of BO-1978 or reference drugs (irinotecan or
etoposide) for 72 hours. The nucleus extracts (NE) were prepared
Table 1. Characteristics of the NSCLC Lines Used in This Study.
Cell Line EGFR TP53 Kras TKI Susceptibility
H460 Wild-type Wild-type Q61H Intrinsic resistance
A549 Wild-type Wild-type G12S Intrinsic resistance
H1299 Wild-type Deficient Wild-type Intrinsic resistance
CL141T Wild-type R248W Wild-type Intrinsic resistance
CL100 Exon 19 deletion ND Wild-type Sensitive
H1650 Exon 19 deletion Wild-type Wild-type Resistance (Pten loss)
H1975 L858R/T790M Wild-type Wild-type Acquired resistance
CL97 G719A/T790M R273H Wild-type Acquired resistance
CL1-5 Wild-type R248W Wild-type Intrinsic resistance
PC9 Exon 19 deletion Wild-type Wild-type Sensitive
PC9/gef B4 Exon 19 deletion Wild-type Wild-type Acquired resistance
(Slug overexpression)
ND, not determined.
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assay, the reaction was carried out by incubation of 2.5 μg of NE and 200
ng of plasmid pEGFP-N1 DNA in 20 μl of topo I reaction buffer (250
mMTris, pH 7.5, 50mMEDTA, 5mMDTT, 0.5MKCl, 25mg/ml of
BSA) at 37°C for 30minutes. The reaction was terminated by the addition
of 2 μl of 10% SDS. The samples were then loaded onto a 1% agarose gel
and electrophoresed at 50 V for 90 minutes. The DNA was visualized by
stainingwith ethidiumbromide. For topo II assay, 10μg ofNE and200ng
of plasmid pEGFP-N1DNAweremixed in 20μl of topo II reaction buffer
(100 mM Tris, pH 7.5, 50 mM MgCl2, 5 mM ATP, 5 mM EDTA,
5 mM DTT, 0.75 M KCl, 150 mg/ml of BSA). The reaction,
electrophoresis, and signal visualization were performed as described above.
Western Blot Analysis
The response of DNA damage biomarker (γH2AX) and proteins
involved in repair of DNA double-strand breaks (DNA-dependent
protein kinase [DNA-PK] and Rad51) and apoptosis (caspase 3 and 7
and poly-ADP ribose polymerase [PARP]) to BO-1978 was determined
by Western blotting [26]. Briefly, H460 cells were treated with various
concentrations of BO-1978 for 72 hours or 2 μM for different time
periods. The whole cell extracts were then electrophoretically separated
on an SDS polyacrylamide gel and transferred onto a polyvinylidene
difluoride membrane (Amersham Biosciences). After blocking, the
membrane was incubated with primary antibodies and then with
horseradish peroxidase–conjugated antirabbit or antimouse secondary
antibodies. Western blot signals were visualized by chemiluminescence
using SuperSignal West Pico chemiluminescence reagent (Pierce).
Antibodies against Rad51 and β-actin were obtained from Genetex;
caspases 3 and 7, PARP, DNA-PK, and secondary antibodies from Cell
Signaling; and γH2AX from EMD Millipore.
Cell Cycle Analysis
H460 cells (2.5 × 105 cells) were treated with various
concentrations of BO-1978 for 24, 48, or 72 hours before being
harvested and fixed with ice-cold 70% ethanol. The cells were stained
with 4 μg/ml of propidium iodide in PBS containing 1% Triton
X-100 and 0.1 mg/ml of RNase A and then subjected to flow
cytometric analysis (FACScan flow cytometer) as previously described
[23]. The distributions of cell cycle phases were determined using
ModFit LT 3.0 software (Verity Software House).
Annexin V–Fluorescein Isothiocyanate (FITC) Apoptosis Analysis
The Annexin V–FITC apoptosis detection kit (eBioscience) was
used to study cell apoptosis induced by BO-1978 according to theinstructions. Cells were exposed to compounds with indicated
concentrations before harvested by trypsinization, then suspended in
Annexin V–FITC and propidium iodide contained binding buffer
and subjected to flow cytometric analysis (FACScan flow cytometer).
Anticancer Activity in Xenograft Mouse Models
The animals used in this study exactly followed the guidelines of the
Academia Sinica Institutional Animal Care and Utilization Committee.
Male athymic nudemice 5weeks of age were obtained from theNational
Laboratory Animal Center (Taipei, Taiwan) and housed for 1 week
before performing experiments [28]. For implantations of xenograft
tumors, an aliquot of H460 (3 × 106), PC9 (5 × 106), PC9/gef B4 (5 ×
106), or H1650 (5 × 106) cells suspended in 100 μl of phosphate
buffered saline (PBS, pH 7.4) was subcutaneously inoculated into the
hind limb of mice. Tested compounds were dissolved in DMSO/Tween
80/saline (10:10:80; v/v/v) and intravenously injected into mice through
tail vein. BO-1978 (40mg/kg) or gefitinib (10mg/kg) [30] was delivered
for 5 consecutive days. Cisplatin (6 mg/kg) was given every 4 days for
three times [31]. To monitor tumor growth, the longest and shortest
diameters of the tumors were measured using calipers. Tumor volume
(mm3) was calculated according to the following formula: tumor
volume = (length × width2)/2. Mouse body weight was also measured as
an indicator of the systemic toxicity of the treatments.
Anticancer Activity in Orthotopic Lung Tumor Models
The orthotopic lung tumor models were performed using intrathoracic
implantation system [25, 32]. In brief, CL1-5/GFP-Luciferase (5 × 106) or
H1650-Luc (2 × 106) cells were suspended in 50 μl of ice-cold Matrigel/
PBS (1:1; v/v) and inoculated into the upper margin of the sixth intercostal
rib on the left anterior axillary line of mice which were anesthetized via
intraperitoneal (i.p.) injection with 2.5% Avertin (250 mg/kg). The
injection depth was about 5 mm. The drug deliveries were performed as
described above. The growths of cancer cells were monitored with In Vivo
Imaging Systems (IVIS Spectrum System; Xenogen Corporation) after i.p.
injection of 150mg/kg ofD-Luciferin (PerkinElmer).Mouse bodyweights
were also monitored as described above.
Pharmacokinetics and Tissue Distribution in Sprague-Dawley
(SD) Rats
The pharmacokinetic study of BO-1978 was performed using SD
rats. In brief, BO-1978 was prepared at the concentration of 10 mg/
ml in 20% ethanol and 80% PEG400. A single dose of BO-1978 was
administrated into healthy male SD rats at the dose of 10 mg/kg via
an indwelling catheter in jugular vein. Serial blood samples were
collected from tail veins at 0, 1, 5, 15, 30, 60, and 120 minutes
postdose from all animals. Concentrations of BO-1978 in blood were
determined by HPLC using Agilent HC-C18 column (4.6 × 100
mm) and UV detector (228 nm). The solution of mobile phase was
35% acetonitrile and 65% 10 mM NaH2PO4 (pH 3.0). For tissue
distribution, liver, heart, spleen, lung, kidney, and brain were sampled
at 30 minutes after BO-1978 administration. The stability of
BO-1978 was determined by incubation of this compound in rat
plasma or cultural medium at room temperature for various time
periods. The residual amount of BO-1978 was analyzed by HPLC.
Preclinical Toxicity in Institute for Cancer Research
(ICR) Mice
The preclinical toxicological studies were conducted according to
the values of LD50 with 6-week-male ICR mice (obtained from the
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below the values of LD50 were given to ICR mice by intravenous
injection. After being monitored for 48 hours (namely, acute toxicity)
and 14 days (namely, subacute toxicity) post drug administrations,
the mice were anesthesia via i.p. injection with 2.5% Avertin (250
mg/kg) before hemospasia from hearts and harvesting heart, lung,
liver, spleen and kidney samples. The whole blood and serum samples
were subjected to complete blood count and blood chemistry (BC)
test, and the main organs were fixed by formalin and embedded in
paraffin block to make tissue sections. BC test was carried out with
the blood chemistry analysis, including aspartate transaminase (AST),
alanine transaminase (ALT), alkaline phosphatase (ALP), blood urea
nitrogen (BUN), creatinine (CRE), and glucose. The tissue sections
were stained with hematoxylin and eosin, and the morphology was
examined by a microscope.
Results
Cytotoxicity of BO-1978 in NSCLC Cells
We have previously demonstrated that indolizino[6,7-b]indoles
have broad spectra of antitumor activity in both culture and xenograft
tumor models [23]. Because lung cancer requires laborious clinical
treatment, we therefore evaluated the anti-NSCLC potential of
BO-1978 (Figure 1A). As summarized in Table 2, BO-1978 is a
potent agent against a batch of 11 NSCLC cell lines, including five
EGFR wild-type and six EGFR mutant cell lines. The IC50 values of
BO-1978 against these NSCLC cells ranged from 1.06 to 3.50 μM,
which were generally lower than those of previously tested therapeutic
agents, such as cisplatin, irinotecan, and etoposide. Although TKIs
are promising drugs against EGFRmutantNSCLC [33], the generation
of resistance to TKIs is a major reason that treatments fail. Among the
cell lines used, except PC9 cells, others were relatively resistant to
gefitinib (Table 2). Intriguingly, BO-1978 also effectively killed the
cells that acquired gefitinib resistance, PC9/gef B4 cells. These results
imply that BO-1978 and its derivatives are potential chemotherapeutic
agents against NSCLC with wild-type or mutant EGFR. Furthermore,
we found that BO-1978 showed no cross-resistance to multiple drug–
resistant and cisplatin-resistant cells (Table 3).Induction of DNA Damage, Cell Cycle Disturbance,
and Apoptosis by BO-1978
The hybrid indolizino[6,7-b]indoles consist of a bis(hydroxy-
methyl)pyrrole pharmacophore and a β-carboline moiety, indicating
that they could form DNA ICL and inhibit topo I and II activitiesTable 2. Comparative Cytotoxicity of BO-1978 with Therapeutic Agents in NSCLC Cells (IC50, μM
Cell Line BO-1978 Cisplatin
H460 1.06 ± 0.11 9.94 ± 0.47
A549 3.15 ± 1.20 31.10 ± 3.03
H1299 3.02 ± 0.65 16.53 ± 0.90
CL1-5 1.47 ± 0.53 2.82 ± 0.28
CL141T 1.32 ± 0.47 2.80 ± 0.36
H1650 3.50 ± 0.10 36.50 ± 8.14
H1975 2.34 ± 0.18 16.09 ± 4.03
CL100 1.51 ± 0.30 6.21 ± 3.64
CL97 1.25 ± 0.18 14.70 ± 0.34
PC9 1.41 ± 0.37 16.35 ± 3.29
PC9/gef B4 1.58 ± 0.33 [1.12] † 34.34 ± 1.62 [2.10]
IC
50
, the concentration of drug required to inhibit cell growth by 50% (mean ± S.D. of three independen
† Numbers in brackets are the resistance factors of PC9/gef B4 to PC9 cells.[23]. We first confirmed that incubation of plasmid DNA with
BO-1978 formed DNA ICLs, as shown by an alkaline gel
electrophoretic assay (Figure 1B). Using a modified comet assay, we
further demonstrated that BO-1978 dose-dependently induced
shortened tail moments in H460 cells irradiated with X-rays,
indicating the formation of DNA ICLs in H460 cells by BO-1978
(Figure 1C). We also observed that topo I and II activities in H460
cells were significantly inhibited by BO-1978 at concentrations
greater than 0.5 μM for 72 hours (Figure 1B), whereas irinotecan and
etoposide were used as positive controls for the topo I and II assays,
respectively. We further observed that BO-1978 dose-dependently
increased the expression levels of proteins that participate in DNA
repair, such as γH2AX, DNA-PK, and Rad51, in H460 cells
(Figure 1E), supporting the suggestion that BO-1978 significantly
induces DNA damage. These results confirmed our previous finding
showing that indolizino[6,7-b]indoles could cause DNA damage via
induction of DNA ICLs and inhibition of topo I and II activities [23].
One striking feature of DNA-damaging agents or topo I and II
inhibitors is cell cycle interference [34]. As shown in Figure 2A,
treatment of H460 cells with BO-1978 (1 to 4 μM) first resulted in S
phase delay at 24 hours and then G2 arrest at 72 hours, whereas
similar results were also observed in BO-1978–treated PC9 and PC9/
gef B4 cells (Supplementary Figure S1). Because we observed that
BO-1978 treatment resulted in increased cell populations at the
sub-G1 phase, an indicator of apoptosis, we examined whether
BO-1978–induced damage could trigger apoptosis by analyzing the
activation of apoptotic executor proteins. As shown in Figure 2B,
BO-1978 dose- and time-dependently induced cleavage of caspases 3
and 7. Using Annexin V staining and flow cytometric analysis, we
confirmed a time-dependent increase in apoptotic cell numbers upon
treatment of H460 cells with BO-1978 at 2 μM (Figure 2C). Taken
together, these results indicate that BO-1978 inhibits topo I and II
and induces DNA ICLs to cause DNA damage and thus to interfere
with cell cycle progression, ultimately triggering apoptosis.
Effective Suppression of EGFR Wild-Type NSCLC Cells by
BO-1978 in Xenograft and Orthotopic Lung Tumor Models
The antitumor activity of BO-1978 against NSCLC cells with
wild-type EGFR was first evaluated using H460 xenografts in nude
mice. To examine the therapeutic efficacy, the maximal tolerant dose
of BO-1978 (40 mg/kg) was given for 5 consecutive days (QDx5). As
shown in Figure 3A, BO-1978 significantly suppressed the growth of
the H460 xenograft to approximately 65% in tumor size, whereas
cisplatin reduced the tumor size to 52%. At the dose used, the effect).
Irinotecan Etoposide Gefitinib
4.18 ± 1.29 7.31 ± 2.56 28.41 ± 7.44
9.29 ± 3.31 22.40 ± 14.39 17.65 ± 1.55
24.46 ± 1.85 15.61 ± 7.45 27.87 ± 2.34
10.53 ± 2.54 12.64 ± 3.93 ND
44.99 ± 15.72 23.32 ± 3.34 20.56 ± 3.34
17.05 ± 4.20 32.48 ± 17.56 32.81 ± 1.38
36.83 ± 14.43 14.12 ± 2.90 50.72 ± 7.58
0.66 ± 0.65 4.30 ± 3.87 27.60 ± 4.70
9.99 ± 3.10 24.40 ± 17.39 8.91 ± 1.65
11.23 ± 1.97 19.33 ± 6.28 0.29 ± 0.05
31.58 ± 4.70 [2.81] 36.66 ± 20.54 [1.90] 25.68 ± 4.68 [88.55]
t experiments).
Table 3. IC50 Values (μM) of BO-1978 in Multiple Drug–Resistant and Cisplatin-Resistant Cells.
Cell Line BO-1978 Vincristine (nM) Doxorubicin Cisplatin
CCRF-CEM 0.46 ± 0.12 2.23 ± 0.19 ND ND
CCRF/VBL 0.41 ± 0.03 [0.78x] † 2128 ± 248.86 [954.3x] ND ND
KB 1.96 ± 0.39 2.16 ± 0.25 ND ND
KB/vin10 1.56 ± 0.51 [0.79x] 510 ± 170 [236.1x] ND ND
MES-SA 0.77 ± 0.08 ND 0.038 ± 0.003 1.82 ± 0.66
MES-SA/dx5 0.47 ± 0.12 [0.61x] ND 2.30 ± 0.98 [60.52x] 2.27 ± 0.73 [1.25x]
NTUB1 1.14 ± 0.32 ND ND 2.97 ± 1.43
NTUB1/P 1.92 ± 0.39 [1.68x] ND ND 62.09 ± 15.30 [20.9x]
IC
50
, the concentration of drug required to inhibit cell growth by 50% (mean ± S.D. of three independent experiments).
† Numbers in brackets are resistance factors.
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caused a body weight loss of approximately 12%. To further confirm
the therapeutic efficacy of BO-1978 in EGFR wild-type NSCLC
cells, we implanted CL1-5/GFP-Luciferase cells into the left lobes of
lungs and traced the tumor growth using an IVIS. As shown in
Figure 3B, treatment of tumor-bearing mice with BO-1978A
B
Figure 2. Interference with cell cycle progression and induction of a
BO-1978. H460 cells were treated with various concentrations of B
distribution of cell cycle phases was analyzed using a flow cytometer
(B) Activation of the apoptotic pathway by BO-1978. The appearance
cells was determined by Western blotting. (C) Induction of apopto
determined using an Annexin V–FITC apoptosis detection kit, as desdramatically abolished the growth of CL1-5/GFP-Luciferase cells in
the lung, whereas cisplatin failed to suppress the growth of CL1-5/
GFP-Luciferase in the lung. Histopathological examination further
confirmed the absence of tumors in the lungs of mice treated with
BO-1978 (Figure 3C). These results revealed that BO-1978 is a potent
therapeutic agent against EGFR wild-type NSCLC cells in the lung.C
poptosis by BO-1978 in H460 cells. (A) Cell cycle interference by
O-1978 (1 to 4 μM) for various time periods (24 to 72 hours). The
andModFit LT 3.0 software (Verity Software House, Topsham, ME).
of cleaved caspase-3 and -7 and PARP in BO-1978–treated H460
sis by BO-1978. The apoptotic cells induced by BO-1978 were
cribed in the Materials and Methods section.
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Figure 3. The therapeutic efficacy of BO-1978 against EGFR wild-type NSCLC cells. (A) Suppression of H460 xenografts by BO-1978.
H460 cells (3 × 106) were subcutaneously implanted in nude mice. When the tumor size reached approximately 100 mm3, the
tumor-bearing mice were intravenously treated with vehicle, BO-1978 (40 mg/kg, daily for 5 consecutive days), or cisplatin (6 mg/kg, three
times every 4 days). The tumor size and body weight were measured at the times indicated. (B) Suppression of orthotopically implanted
CL1-5/GFP-Luciferase cells by BO-1978. CL1-5/GFP-Luciferase cells (5 × 106) were orthotopically implanted in the lungs of nude mice.
The tumor-bearing mice were treated with vehicle, BO-1978, or cisplatin, as described above. (Left) The representative images of mice
implanted with CL1-5/GFP-Luciferase cells and treated with drugs. (Middle and right) The quantitative signals of luciferase (p/s per cm2
per sr) and the relative bodyweights of mice treated with vehicle, BO-1978, or cisplatin, respectively. p, photon; sr, steradian. (C) No tumor
formation in the lungs of orthotopically implanted mice treated with BO-1978. On day 19, the lungs were harvested from mice treated
with vehicle, BO-1978, or cisplatin; histopathologically sectioned; and stained with hematoxylin and eosin.
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NSCLC Cells by Combination Treatment with BO-1978
and Gefitinib
Although we found that BO-1978 significantly killed mutant EGFR
NSCLC cells in vitro (Table 1), we further investigated the efficacy of this
compound and its combination with gefitinib to suppress growth of
NSCLC cells with mutant EGFR.We first performed an alamarBlue assayto demonstrate enhanced cytotoxicity by co-treatment with BO-1978 and
gefitinib in PC9, PC9/gef B4, H1650, and H1975 cells in the toxic dose
range (Figure 4A). The effective dose ratios of gefitinib to BO-1978 used
were relatively associated with the resistance of cells to gefitinib. The ratio
was 0.6 to 1 in gefitinib-sensitive PC9 cells, whereas the ratios were 15 to 1
in gefitinib-resistant PC9/gef B4 cells and 10 to 1 in H1650 and H1975
cells. Furthermore, we observed that treatment of cells with BO-1978
206 A Derivative of Indolizino[6,7-b]Indole for NSCLC Chen et al. Neoplasia Vol. 18, No. 4, 2016(2 μM) alone resulted in increased expression of γH2AX, a DNA damage
marker, at 24 hours that then declined at 72 hours, implying that
BO-1978–inducedDNAdamage was gradually repaired in PC9 and PC9/
gef B4 cells. Treatment of cells with gefitinib (4 μM) alone significantly
reduced the protein expression levels of DNA-PK and Rad51, which are
essentially involved in DNA repair (Figure 4B). Intriguingly, upon
co-treatment of PC9 andPC9/gef B4 cells withBO-1978 and gefitinib, the
protein expression levels of DNA-PK and Rad51 were suppressed, whereas
γH2AX remained and accumulated in the cells (Figure 4B). These resultsA
B
Figure 4. Enhancement of BO-1978–induced toxic effects in EGF
suppression of cell growth by combination treatment of EGFR mutan
PC9/gef B4, H1650, and H1975 cells were treated with BO-1978,
determined using an alamarBlue assay, as described in the Materials
expression and suppression of DNA repair proteins (DNA-PK and R
BO-1978, gefitinib, or the combination for 24 and 72 hours. At the en
Rad51 expression levels were analyzed by Western blotting.indicate that gefitinib likely suppresses repair of BO-1978–inducedDNAdamage.
Consistently, combination treatment of PC9andPC9/gefB4 cellswithBO-1978
and gefitinib also resulted in increased apoptotic cells (Figure 5,A andB).
Effective Suppression of EGFR Mutant NSCLC Cells by
Combination Treatment with BO-1978 and Gefitinib in
Xenograft and Orthotopic Lung Tumor Models
The xenograft models of PC9, PC9/gef B4, H1650, and H1975
cells were adopted to examine the therapeutic efficacy of BO-1978R mutant NSCLC cells upon gefitinib treatment. (A) Synergistic
t NSCLC with BO-1978 and gefitinib. Logarithmically growing PC9,
gefitinib, or the combination for 72 hours. The cell growth was
and Methods section. (B) Increased DNA damage marker (γH2AX)
ad51) by gefitinib. PC9 and PC9/gef B4 cells were treated with
d of treatment, the cells were harvested, and γH2AX, DNA-PK, and
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cells. As shown in Figure 6, daily treatment with BO-1978 at the dose
of 40 mg/kg for 5 consecutive days significantly suppressed the
growth of PC9, PC9/gef B4, H1650, and H1975 xenograft tumors
by 55%, 73%, 30%, and 26%, respectively, without significant
reductions in body weight during the treatments. The suppression
effects on xenograft growth by gefitinib administered at the dose of 10
mg/kg for 5 consecutive days in PC9, PC9/gef B4, H1650, and
H1975 xenograft mouse models were approximately 36%, 49%,
51%, and 1%, respectively. The efficacy of cisplatin was included for
comparison. BO-1978 was more potent than cisplatin and gefitinib
against PC9, PC9/gef B4, and H1975 cells but not H1650 cells.
However, the combination treatment of BO-1978 and gefitinibA
B
Figure 5. Increasing BO-1978–induced apoptotic cells with gefitini
growing PC9 and PC9/gef B4 cells were treated with BO-1978 (2 μM), g
combination for 72 hours. At the end of treatment, the cells were harv
V–FITC apoptosis detection kit. The data on the right are the means
.001 according to Student’s t test.promisingly suppressed the growth of xenografts by 64%, 83%, 83%,
and 55% in PC9, PC9/gef B4, H1650, and H1975 cells, respectively.
These results indicate that the combination of BO-1978 with
gefitinib could be an effective regimen for treatment of EGFR mutant
NSCLC cells.
To further confirm the therapeutic efficacy of BO-1978 against
EGFR mutant NSCLC cells, we established H1650-Luc cells by
transfection of luciferase-expressing plasmids into cells and then
intrathoracically implanted them into the left lobes. Two days after
implantation, the mice were randomly grouped and received treatment.
As shown in Figure 7, we found that H1650-Luc cells were resistant to
gefitinib treatment alone but were effectively suppressed by BO-1978
treatment alone. Furthermore, the combination of BO-1978 withb treatment in PC9 (A) and PC9/gef B4 cells (B). Logarithmically
efitinib (0.4 μM for PC9 cells and 30 μM for PC9/gef B4 cells), or the
ested and subjected to analysis of apoptotic cells using an Annexin
and SD of three independent experiments. ** and ***, P b .01 and
AB
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Figure 6. Antitumor activity of BO-1978 in EGFR mutant NSCLC xenografts. Aliquots of 5 × 106 PC9 (A), PC9/gef B4 (B), H1650 (C), and
H1975 (D) cells were subcutaneously implanted in nude mice. When tumor sizes reached approximately 100 mm3, the mice were treated
with vehicle, BO-1978 (40 mg/kg, daily for 5 consecutive days), gefitinib (10 mg/kg, daily for 5 consecutive days), BO-1978 + gefitinib, or
cisplatin (6 mg/kg, three times every 4 days). The tumor volumes and body weights were monitored at the indicated times.
208 A Derivative of Indolizino[6,7-b]Indole for NSCLC Chen et al. Neoplasia Vol. 18, No. 4, 2016gefitinib completely suppressed tumor cell signaling in the orthotropic
model (Figure 7). Consistently, the treatment did not lead to severe
damage in terms of body weight changes. These results confirmed the
antitumor activity of BO-1978 alone and in combination in the lungs.
Pharmacokinetics of BO-1978 in SD Rats
By incubation of BO-1978 in rat plasma or cultural medium at
room temperature, we found thast BO-1978 was relatively stable.
The half-lives of BO-1978 in rat plasma and culture medium were
89.41 ± 5.62 (n = 3) and 36.83 ± 2.19 hours (n = 3), respectively. The
whole-blood pharmacokinetics of BO-1978 was evaluated in healthy
male SD rats following a single intravenous administration ofBO-1978 at a dose of 10 mg/kg. BO-1978 concentrations in plasma
following drug administration were determined by HPLC and are
shown in Supplementary Figure S2. Accordingly, the initial
concentration or C0 (drug administration at time 0 minute) and
the half-life (t1/2) of BO-1978 were 8.63 ± 2.18 μg/ml (i.e., 27.8 ±
7.0 μM) and 23.50 ± 7.09 minutes, respectively. The area under the
curve (AUC0-last) was estimated to be 188.10 ± 45.99 min μg/ml.
The systemic clearance of BO-1978 was estimated to be 56.24 ±
14.90 ml/min per kg, which is approximately 19% of the cardiac
output of rats (approximately 296 ml/min per kg), indicating that
BO-1978 in rats has a medium clearance rate. The apparent volume
of distribution at steady state was 1.46 ± 0.29 l/kg, which was more
AB
C
Figure 7. Suppression of orthotopic growth of H1650-Luc cells by
BO-1978 alone or in combination with gefitinib. H1650-Luc cells
(2 × 106) were intrathoracically implanted in the left lobes of nude
mice. On day 2, the mice were treated with BO-1978 alone or in
combination with gefitinib, as described in Figure 6. Tumor growth
was monitored by IVIS. (A) Representative images of tumor
growth; (B) averaged photon intensity; and (C) body weight.
able 4. Tissue Distribution of BO-1978 in Rats.
issue BO-1978 (μg/ml or μg/g)
lood 1.59 ± 0.48
iver 10.71 ± 1.96
eart 1.79 ± 0.72
pleen 0.48 ± 0.08
ung 3.13 ± 1.44
idney 2.19 ± 0.12
rain 3.97 ± 0.96
Tissue samples were harvested 30 minutes after drug administration. The data are expressed as the mean ±
D (n = 6).
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BO-1978 may be moderately distributed into tissues. The mean
residence time was 27.34 ± 7.97 minutes. The tissue distribution of
BO-1978 in rats is summarized in Table 4. At 30 mintes after
BO-1978 administration, the drug was widely distributed in various
tissues, including liver, lung, and brain. However, how BO-1978 is
metabolized in animals warrants our further investigation.
Limited Toxicity of BO-1978 in ICR Mice
Toxicity/safety is one of the main issues for new drug development.
In our animal studies, we did not observe severe body weight changes
in mice treated with either BO-1978 alone or BO-1978 plus
gefitinib. To further investigate the toxic effect of BO-1978, we
performed an acute toxicity study using ICR mice. First, we foundthat the LD50 value (50% lethal concentration) for BO-1978 was
93.7 mg/kg in ICR mice. We then studied the toxicity/safety of
BO-1978 at the effective dose. The ICR mice were intravenously
administered 40 mg/kg of BO-1978, and the blood samples and
major organs were harvested on days 2 and 14 for analysis of their
toxic effects. The results of the complete blood count and BC
examinations are summarized in Table 5. No evidence of anemia,
white cell abnormality, or hematopoietic deficiency was noted in mice
administered with BO-1978. Although we observed obvious
increments of AST and ALT post 48 hours in the BC test, the liver
damage caused by BO-1978 recovered to normal range on day 14.
However, we found that the hepatocytes and the hepatoportal area
were intact, and no anoxic signs were noted around the central vein in
the liver sections (Supplementary Figure S3). These results were also
consistent with the findings showing that more BO-1978 was
distributed to the liver than other organs (Table 5). The changes in
BUN, CRE, and glucose were negligible, suggesting that renal
metabolic functions were not excessively affected. In addition to the
liver, histopathological examinations revealed no apparent alterations
in the heart, lung, spleen and kidney. As shown in Supplementary
Figure S2, BO-1978–treated mice had intact structures in the
myocardium, septa, and the four- and three-chamber sections of the
heart, indicating no cardiac injury, ventricular dilation, or ventricular
hypertrophy. The lung sections revealed that BO-1978–treated mice
had clear alveoli without obstruction of the airway. We did not find
any lymphocyte depletion or enhancement within the spleens of
BO-1978–treated mice. For the kidneys, the structure of the renal
glomerulus was intact, and no filtrate in Bowman’s capsules or
detached renal tubular debris was detected in the kidneys of
BO-1978–treated mice. In summary, BO-1978 at a dose of 40 mg/
kg did not cause apparent toxic effects in the major organs except for
slight and recoverable liver damage.
Discussion
The present study was conducted to understand the anti-NSCLC
activity of indolizino[6,7-b]indoles. Accordingly, we have demonstrated
that the selected derivative of indolizino[6,7-b]indoles, BO-1978, is a
potent agent against a variety of NSCLC cells in vitro and in vivo.
Because BO-1978 at the doses used did not cause obvious toxicity in
mice, wemay consider that BO-1978 has high potential to be developed
into a candidate drug for NSCLC treatment.
BO-1978 is a chemical with multimodal activities, including
inducing DNA ICLs and inhibiting topo I and II activity. Because the
lesions of DNA ICLs are generally highly toxic to cells, a variety of
DNA ICL compounds have been widely used as chemotherapeutic
agents against different types of cancer [35, 36]. Our results showed
that BO-1978 induces DNA ICLs in vitro and in vivo and, hence,T
T
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H
S
L
K
B
S
Table 5. Blood Cell and Blood Chemistry Tests following BO-1978 Administration after 48 Hours
and 14 Days in ICR Mice.
Items Ctrl (n = 12) BO-1978
48 Hours (n = 8) 14 Days (n = 6)
WBC (109/l) 3.92 ± 1.40 2.43 ± 1.19 4.00 ± 0.97
NEU (109/l) 0.67 ± 0.24 0.45 ± 0.21 0.82 ± 0.47
LYM (109/l) 2.95 ± 1.16 1.83 ± 1.17 2.86 ± 0.88
MONO (109/l) 0.12 ± 0.06 0.05 ± 0.04 0.11 ± 0.09
EOS (109/l) 0.10 ± 0.04 0.05 ± 0.04 0.12 ± 0.13
BASO (109/l) 0.09 ± 0.05 0.06 ± 0.03 0.09 ± 0.03
RBC (1012/l) 7.73 ± 0.51 7.14 ± 0.38 7.81 ± 0.33
HGB (g/dl) 12.99 ± 0.42 11.96 ± 0.53 12.78 ± 0.42
HCT (%) 44.69 ± 2.59 41.13 ± 1.95 44.02 ± 1.18
MCV (fL) 57.83 ± 1.49 57.61 ± 1.27 56.40 ± 1.69
MCH (pg) 16.86 ± 0.89 16.75 ± 0.45 16.38 ± 0.52
MCHC (g/dl) 29.13 ± 1.30 29.07 ± 0.40 29.05 ± 0.46
PLT (109/l) 915.42 ± 147.50 786.10 ± 90.60 958.00 ± 178.31
AST (U/l) 90.09 ± 38.80 220.27 ± 153.45 86.14 ± 25.25
ALT (U/l) 39.75 ± 12.46 156.25 ± 236.88 44.87 ± 19.72
ALP (U/l) 244.14 ± 49.91 297.50 ± 72.11 233.50 ± 36.74
BUN (mg/dl) 26.07 ± 4.64 19.48 ± 2.03 23.95 ± 1.71
CRE (mg/dl) 0.21 ± 0.11 0.18 ± 0.15 0.17 ± 0.05
BASO, basophil; EOS, eosinophil; HCT, hematocrit; HGB, Hemoglobin; LYM, lymphocyte;
MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration;
MCV, mean corpuscular volume; MONO, monocyte; NEU, neutrophil; PLT, platelet; RBC, red
blood cell; WBC, white blood cell.
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cophoric group of BO-1978 responsible for attacking DNA to form
ICLs is bis(hydroxymethyl)pyrrole [23], which displays potent
antitumor activity [37, 38]. Numerous anticancer chemotherapeutics
target topo I and II by either catalytic inhibition or poisoning [39,
40]. β-Carboline alkaloids are an important class of natural and synthetic
medicinal molecules exerting their anticancer activities through diverse
mechanisms [41], such as topo I/II inhibition [19, 20]. Recently, a variety
of β-carboline hybrids have been synthesized and evaluated against different
diseases, including cancer and neurological disorders [42–44]. We revealed
that BO-1978, also a β-carboline hybrid [23], could inhibit topo I/II. Our
results support that the conjugation of DNA ICL activity and
topoisomerase inhibitory activity into a single molecule may exert a unique
mode to kill NSCLC cells.
Clinicians still endeavor to find effective regimens for the treatment
of NSCLC patients who do not harbor targetable genetic
abnormalities [17, 45, 46]. In the cytotoxicity study, BO-1978
exhibited strong antitumor activity in vitro in NSCLC lines
containing Kras mutations (H460 and A549 cells), p53 mutations
(H1299, CL1-5, and CL141T cells), TKI-sensitive mutant EGFRs
(PC9 cells), and TKI-resistant mutant EGFRs (PC9/gef B4, H1650,
H1975, CL97, and CL100 cells). Unfortunately, a major portion of
NSCLC patients harboring wild-type EGFR cannot control the
disease using current treatments, including cisplatin-based adjuvant
chemotherapy or TKIs [47]. These results show that BO-1978
effectively suppresses subcutaneously transplanted EGFR wild-type
NSCLC cells in nude mouse models. Furthermore, orthotopically
implanted CL1-5 cells, an EGFR wild-type NSCLC cell line, were
completely eradicated by BO-1978 treatment, whereas cisplatin failed
to suppress their growth in the lung. Intriguingly, our results also
showed not only that BO-1978 was more cytotoxic to multiple drug–
resistant cells than their parental cells but also that the compound
displayed no cross-resistance in cisplatin-resistant cells. Therefore, the
potential of BO-1978 as an anti-NSCLC agent without targetable
alterations warrants our further investigation.Because of the rapid development of resistance results in treatment
failure [48], there is an unmet clinical need to search for effective
third- or fourth-line therapeutic agents against TKI-resistant NSCLC
[48, 49]. Several targeted therapies, including inhibitors of EGFR,
anaplastic lymphoma kinase or MET, and others, are currently either
clinically available or under development [16]. Herein, we demon-
strated that BO-1978 could also overcome TKI resistance in several
EGFR mutant NSCLC cells. In addition, combination treatment of
PC9 or PC9/gef B4 cells with BO-1978 and gefitinib resulted in
accumulation of γH2AX, a marker for monitoring DNA damage
[50], and decreased Rad51 and DNA-PK, core components of DNA
double-strand break repair [49, 51], indicating that EGFR inhibition
by gefitinib resulted in suppression of DNA repair and potentiated
BO-1978 toxicity. Combination therapy using TKIs and chemo-
therapeutic agents has been well reported in the literature [52].
Although BO-1978 treatment moderately suppressed the growth of
H1650 xenograft, the signals of orthotopically implanted H1650 cells
in the lungs were almost completely eliminated by combination
treatment of BO-1978 and gefitinib. These results implicate that the
therapeutic efficacy of DNA ICL agents could be further improved by
rational combination therapy with DNA repair inhibitors or targeted
therapeutic agents. However, the reason why BO-1978 actively
eradicates tumor cells growing in the lung is unclear. As tumor
microenvironment [16] and drug distribution [53] are apparently
different between xenograft and orthotopic lung tumor models, the
distribution of BO-1978 in various organswarrants further investigation.
Our single-dose pharmacokinetic study showed that the initial t1/2 of
BO-1978was 23.50 ± 7.09minutes. Because the drugmetabolic rate in
animals is generally higher than that in humans, the elimination t1/2 of
BO-1978 is close to that of bendamustine (approximately 40 minutes)
[54], a unique alkylating agent used for treatment of chronic
lymphocytic leukemia by the United States Food and Drug
Administration in 2008 [55]. The medium clearance rate of
BO-1978 suggests that we could administer BO-1978 daily or every
other day. The value of volume of distribution at steady state was more
than two-fold the total body water of rats, indicating the moderate
distribution of BO-1978 in tissues. Slightly higher levels of BO-1978
distributed in the liver may cause slight but recoverable liver injury.
Drug development usually fails because of high toxicity [56].
However, for cancer treatment, current chemotherapeutic agents lead
to severe drug toxicity, such as thrombocytopenia, leukocytopenia, and
interstitial pneumonitis resulting from treatment with mitomycin C;
nephrotoxicity, ototoxicity, and neurotoxicity from cisplatin and
carboplatin; and cardiac toxicity from doxorubicin [57–59]. With
regard to drug toxicity, BO-1978 has limited toxicity at the effective dose
in mice. Furthermore, there is no significant body weight loss in mice
treated with BO-1978 for 5 consecutive days in our animal studies,
indicating that these compounds did not cause severe systematic toxicity.
In conclusion, our present study demonstrates that BO-1978 is a
potent agent against EGFR wild-type and mutant NSCLCs in an
orthotopic mouse model and has limited toxicity in mice. These results
suggest that BO-1978, a derivative of indolizino[6,7-b]indoles with topo
I/II inhibition andDNA ICL induction activities, is a potential candidate
for future development as a therapeutic agent against NSCLC.
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